Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

123
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
123
Hazard Ratio01:12

Hazard Ratio

91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
91

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Singular Value Decomposition-Based Coil Combination Improves the Accuracy and Noise-Robustness of Quantitative Susceptibility Maps.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical and biochemical characterization of amyotrophic lateral sclerosis in a CHCHD10 R15L family.

Brain : a journal of neurology·2026
Same author

Assessing verbal and spatial memory via smartphone.

Frontiers in digital health·2026
Same author

Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review.

BMC medicine·2026
Same author

Utilization of a Deep Learning Algorithm for Automated Segmentation of Median Nerve from Ultrasound Obtained from the Distal Forearm and Wrist.

Bioengineering (Basel, Switzerland)·2025
Same author

Distinct medial temporal volumetric signatures in extra-medial temporal lobe lesional epilepsy.

Epilepsia open·2025

相关实验视频

Updated: Jun 11, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K

对多发性硬化症治疗的数据驱动风险/益处估计器.

Bibiana Bielekova1, Tianxia Wu2, Peter Kosa1

  • 1Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

medRxiv : the preprint server for health sciences
|October 7, 2024
PubMed
概括

对多发性硬化症 (MS) 疾病修饰性治疗 (DMT) 进行个性化风险效益分析至关重要. 目前的DMT可能会对未被选择参加临床试验的患者造成更多的伤害而不是益处,这凸显了个性化治疗策略的必要性.

更多相关视频

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.5K

相关实验视频

Last Updated: Jun 11, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.5K

科学领域:

  • 神经学 神经学
  • 临床药理学 临床药理学
  • 生物统计学 生物统计学

背景情况:

  • 多发性硬化症 (MS) 的疾病修饰疗法 (DMT) 通常在预先选择的患者队列中进行评估.
  • 在临床实践中对DMT的广泛处方需要了解个性化的风险-益处概况.

研究的目的:

  • 开发数据驱动的计算,用于MS DMTs的个性化风险/收益比率.
  • 通过个性化风险-收益评估,优化多发性硬化症护理.

主要方法:

  • 61个2b/3期随机对照试验 (46,611名患者,91,787名患者年) 的再分析和整合.
  • 提取和计算患者特征,以识别和调整回归模型中的偏差.
  • 用年龄调整的死亡率表和危险比率估计DMT的死亡风险.

主要成果:

  • 患者的基线特征显著影响残疾进展和DMT疗效.
  • 德米特疗法的疗效与多发性硬化症的病变活性有正相关,与年龄,疾病持续时间和残疾有负相关.
  • 随着治疗的持续时间,DMT的疗效迅速下降,而随着年龄,残疾和并发症的增加,风险会增加.

结论:

  • 在临床试验标准之外对患者开处方DMT可能会导致伤害超过益处.
  • 优化多发性硬化症护理包括在发病时启动高效疗法,并降级到具有较低感染风险的DMT.
  • 开发针对不依赖于损伤活动的进展机制的新型DMT至关重要.